Item 16. Form 10-K Summary

Not applicable.

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Eli Lilly and Company


By						/s/ David Ricks
David Ricks
Chair, President, and Chief Executive Officer

February 21, 2024

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on February 21, 2024 by the following persons on behalf of the Registrant and in the capacities indicated.


Signature						Title

/s/ David Ricks						Chair, President, and Chief Executive Officer (principal executive officer)
DAVID RICKS

/s/ Anat Ashkenazi						Executive Vice President and Chief Financial Officer (principal financial officer)
ANAT ASHKENAZI

/s/ Donald Zakrowski						Senior Vice President, Finance, and Chief Accounting Officer (principal accounting officer)
DONALD ZAKROWSKI

/s/ Ralph Alvarez						Director
RALPH ALVAREZ

/s/ Katherine Baicker, Ph.D.						Director
KATHERINE BAICKER, Ph.D.

/s/ Erik Fyrwald						Director
ERIK FYRWALD

/s/ Mary Lynne Hedley, Ph.D.						Director
MARY LYNNE HEDLEY, Ph. D.

/s/ Jamere Jackson						Director
JAMERE JACKSON

/s/ Kimberly Johnson						Director
KIMBERLY JOHNSON

/s/ William Kaelin, Jr., M.D.						Director
WILLIAM KAELIN, JR., M.D.

/s/ Juan Luciano						Director
JUAN LUCIANO

/s/ Marschall Runge, M.D., Ph.D.						Director
MARSCHALL RUNGE, M.D., Ph.D.

/s/ Gabrielle Sulzberger						Director
GABRIELLE SULZBERGER

/s/ Karen Walker						Director
KAREN WALKER

Trademarks Used In this Annual Report on Form 10-K

Trademarks or service marks owned by Eli Lilly and Company or its affiliates, when first used in each item of this Annual Report on Form 10-K, appear with an initial capital and are followed by the symbol ® or ™, as applicable. In subsequent uses of the marks in the item, the symbols may be omitted.

Actos® is a registered trademark of Takeda Pharmaceutical Company Limited.

Baqsimi® is a registered trademark of Amphastar Pharmaceuticals, Inc.

Glyxambi®, Jardiance®, Jentadueto®, Synjardy®, Trajenta®, and Trijardy® are trademarks of Boehringer Ingelheim International GmbH.

Tyvyt® is a registered trademark of Innovent Biologics (Suzhou) Co., Ltd.

Qbrexza® is a registered trademark of Journey Medical Corporation.

Zyprexa® is a registered trademark of Cheplapharm Arzneimittel GmbH.

Previous: Item 15. Exhibits and Financial Statement Schedules